Evaluation of Beta-Absorbed Fractions in a Mouse Model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu Radionuclides

Journal Article · Mon Aug 01 00:00:00 EDT 2005 · Cancer Biotherapy & Radiopharmaceuticals

DOI:https://doi.org/10.1089/cbr.2005.20.436· OSTI ID:859986

Miller, William H; Hartmann-Siantar, Christine; Fisher, Darrell R; Descalle, Marie-Anne; Daly, Tom; Lehmann, Joerg; Lewis, Michael R; Hoffman, Timothy J; Smith, Jeff; Situ, Peter D; Volkert, Wynn A

Several short-lived, high-energy beta emitters are being proposed as the radionuclide components for molecular-targeted potential cancer therapeutic agents. The laboratory mice used to determine the efficacy of these new agents have organs that are relatively small compared to the ranges of these high-energy particles. The dosimetry model developed by Hui et al. was extended to provide realistic beta-dose estimates for organs in mice that received therapeutic radiopharmaceuticals containing 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177 Lu. Major organs in this model included the liver, spleen, kidneys, lungs, heart, stomach, small and large bowel, thyroid, pancreas, bone, marrow, carcass, and a 0.025-g tumor. The study as reported in this paper verifies their results for 90Y and extends them by using their organ geometry factors combined with newly calculated organ self-absorbed fractions from PEREGRINE and MCNP. PEREGRINE and MCNP agree to within 8% for the worst-case organ with average differences (averaged over all organs) decreasing from 5% for 90Y to 1% for 177Lu. When used with typical biodistribution data, the three different models predict doses that are in agreement to within 5% for the worst-case organ. The beta-absorbed fractions and cross-organ-deposited energy provided in this paper can be used by researchers to predict mouse-organ doses and should contribute to an improved understanding of the relationship between dose and radiation toxicity in mouse models where use of these isotopes is favorable.

• Research Organization: Pacific Northwest National Lab. (PNNL), Richland, WA (United States)
• Sponsoring Organization: USDOE
• DOE Contract Number: AC05-76RL01830
• OSTI ID: 859986
• Report Number(s): PNWD-SA-7072; TRN: US0504839
• Journal Information: Cancer Biotherapy & Radiopharmaceuticals, Vol. 20, Issue 4
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
DOSIMETRY
DRUGS
GEOMETRY
KIDNEYS
LIVER
LUNGS
MICE
NEOPLASMS
ORGANS
PANCREAS
RADIATIONS
RADIOISOTOPES
RADIOPHARMACEUTICALS
SPLEEN
STOMACH
THYROID
TOXICITY
90Y
188Re
166Ho
149Pm
177Lu
64Cu
beta-emitter dosimetry
Medical Internal Radiation Dose (MIRD) estimates
mouse model
molecular targeted radionuclide therapy
radioimmunotherapy
MCNP
PEREGRINE
small-scale dosimetry
S-factors